|
|
|
| Tuberculosis induced by Sintilimab in patients with non-small cell lung cancer: a case report |
| LIU Di1,2 GONG Jun2 LIAO Zhengkai2 ZHOU Yunfeng2 |
1.Medicine Division, Wuhan University, Hubei Province, Wuhan 430072, China;
2.Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Province, Wuhan 430071, China |
|
|
|
Abstract Programmed death receptor-1/ programmed death-ligand-1 antibody has been widely used in the treatment of malignancies, it has been gradually reported as an immune-related adverse event. The case was a 67-year-old male patient with stage Ⅳ non-small cell lung cancer who was treated with second-line chemotherapy combined with Sintilimab after first-line treatment progression. Subsequently, the patient developed cough, wheezing and night sweats, further examination showed that mycobacterium tuberculosis was cultured, and he was diagnosed with tuberculous pleurisy. Tuberculosis induced by Sintilimab in patients with advanced non-small cell lung cancer after chemoradiotherapy has not been reported. In order to raise clinicians’ awareness of the potential risk of Sintilimab-induced tuberculosis, this paper is hereby reported.
|
|
|
|
|
|
[1] Darvin P，Toor SM，Sasidharan Nair V，et al. Immune checkpoint inhibitors：recent progress and potential biomarkers [J]. Exp Mol Med，2018，50（12）：1-11.
[2] Alsaab HO，Sau S，Alzhrani R，et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy：Mechanism，Combinations，and Clinical Outcome [J]. Front Pharmacol，2017，8（8）：561.
[3] Sun C，Mezzadra R，Schumacher TN. Regulation and Function of the PD-L1 Checkpoint [J]. Immunity，2018，48 （3）：434-452.
[4] Wu Y，Chen W，Xu ZP，et al. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade，Knockdown，or Inhibition [J]. Front Immunol，2019，10 （10）：2022.
[5] Mok TSK，Wu YL，Kudaba I，et al. Pembrolizumab versus chemotherapy for previously untreated，PD-L1-expressing，locally advanced or metastatic non-small-cell lung cancer （KEYNOTE-042）：a randomised，open-label，controlled，phase 3 trial [J]. Lancet，2019，393（10183）：1819-1830.
[6] Rittmeyer A，Barlesi F，Waterkamp D，et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer （OAK）：a phase 3，open-label，multicentre randomised controlled trial [J]. Lancet，2017， 389（10066）：255-265.
[7] Anastasopoulou A，Ziogas DC，Samarkos M，et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors：current evidence and clinical practice recommendations [J]. J Immunother Cancer，2019，7（1）：239.
[8] Jensen KH，Persson G，Bondgaard AL，et al. Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer [J]. Acta Oncol，2018， 57（8）：1127-1128.
[9] Tsai CC，Chen JH，Wang YC，et al. Reactivation of pulmonary tuberculosis during anti-programmed death-1 （PD-1） treatment [J]. Qjm，2019，112（1）：41-42.
[10] Picchi H，Mateus C，Chouaid C，et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology：reactivation of tuberculosis after anti PD-1 treatment [J]. Clin Microbiol Infect，2018，24（3）：216-218.
[11] Liu X，Yi Y. Recent updates on Sintilimab in solid tumor immunotherapy [J]. Biomark Res，2020，8（1）：69-69.
[12] Zhang L，Mai W，Jiang W，et al. Sintilimab：A Promising Anti-Tumor PD-1 Antibody [J]. Front Oncol，2020，10（10）：594558.
[13] Yang Y，Wang Z，Fang J，et al. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC：a Randomized，Double-Blind，Phase 3 Study （Oncology pRogram by InnovENT anti-PD-1-11）[J]. J Thorac Oncol，2020，15（10）：1636-1646.
[14] Zhang Y，Zhao M，Cao S，et al. Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient：A case report [J]. Thorac Cancer，2020，11（9）：2717-2722.
[15] Philips JA，Ernst JD. Tuberculosis pathogenesis and immunity [J]. Annu Rev Pathol，2012，7（1）：353-384.
[16] Tousif S，Singh Y，Prasad DV，et al. T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection [J]. PLoS One，2011，6（5）：e19864.
[17] Barber DL，Mayer-Barber KD，Feng CG，et al. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition [J]. J Immunol，2011，186（3）：1598-1607.
[18] Barber DL，Sakai S，Kudchadkar RR，et al. Tuberculosis following PD-1 blockade for cancer immunotherapy [J]. Sci Transl Med，2019，11（475）：eaat2702.
[19] Suárez I，Fünger SM，Kr?觟ger S，et al. The Diagnosis and Treatment of Tuberculosis [J]. Dtsch Arztebl Int，2019， 116 （43）：729-735.
[20] Dobler CC，Cheung K，Nguyen J，et al. Risk of tuberculosis in patients with solid cancers and haematological malignancies：a systematic review and meta-analysis [J]. Eur Respir J，2017，50（2）：1700157.
[21] Suliman AM，Bek SA，Elkhatim MS，et al. Tuberculosis following programmed cell death receptor-1 （PD-1） inhibitor in a patient with non-small cell lung cancer. Case report and literature review [J]. Cancer Immunol Immunother，2020，69（10）：1942.
[22] Takata S，Koh G，Han Y，et al. Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents [J]. J Infect Chemother，2019，25（1）：54-58.
[23] Fujita K，Terashima T，Mio T. Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis [J]. J Thorac Oncol，2016，11（12）：2238-2240.
[24] Kato Y，Watanabe Y，Yamane Y，et al. Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer：a case report [J]. Immunotherapy，2020，12（6）：373-378.
[25] Machuca I，Vidal E，de la Torre-Cisneros J，et al. Tuberculosis in immunosuppressed patients [J]. Enferm Infecc Microbiol Clin，2018，36（6）：366-374. |
|
|
|
